Polyclonal Antibody to Coagulation Factor V (F5)
| Code | Size | Price |
|---|
| PAA675Hu02-20ul | 20ul | £81.00 |
Quantity:
| PAA675Hu02-100ul | 100ul | £149.00 |
Quantity:
| PAA675Hu02-200ul | 200ul | £200.00 |
Quantity:
| PAA675Hu02-1ml | 1ml | £454.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
FV; FVL; PCCF; Proaccelerin; Labile Factor; Factor V Leiden; Accelerator Globulin; Activated protein C cofactor; Proaccelerin, labile factor
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Coagulation Factor V
Reactivity:
Mu;Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml<br/>Immunohistochemistry in paraffin section: 5-20ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Coagulation Factor V (F5) | RPA675Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||